Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors

About this update from Thiogenesis Therapeutics Corp

San Diego, California--(Newsfile Corp. - June 17, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation cysteamine-based therapies for rare diseases, including cystinosis and primary mitochondrial diseases, today announced the appointment of Gilad Aharon, PhD, to its Board of Directors. Dr. Aharon is a Co-Founder and Portfolio Manager at Rosalind Advisors, Inc., a Toronto-based life sciences institutional investor. The appointment follows Rosalind Advisors' investment in Thiogenesis' recently completed, non-brokered private placement. Dr. Aharon holds a Ph.D. in Biophysics and Molecular Biology from the University of Toronto. "Gil brings significant experience and depth of insight in the life sciences sector, and we look forward to working together in advancing TTI-0102," said Patrice Rioux, Chief Executive Officer of Thiogenesis. Dr. Aharon added, "Thiogenesis has taken a disciplined approach to developing TTI-0102, with a clear focus on its late-stage cystinosis program while continuing development in primary mitochondrial disease, including Leigh syndrome spectrum disorders. By joining the board, Rosalind is committing to support the Company's execution on a clear set of near-term clinical and regulatory objectives addressing areas of high unmet medical needs." The Company also wishes to announce, that further to its news release of June 3, 2026, the TSX Venture Exchange has issued its final acceptance for the Company's previously announced non-brokered private placement. About Rosalind Advisors, Inc. Rosalind Advisors, Inc. is a Toronto-based Investment Manager founded in 2006 that specializes in the biotechnology and life sciences sectors. About Thiogenesis Based in San Diego, California, Thiogenesis Therapeutics Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also advancing research and clinical work in primary mitochondrial diseases, initially focused on Leigh syndrome spectrum disorders. For further informat...

View stock analysis, news, and events for Thiogenesis Therapeutics Corp